Patents Assigned to Alnylam Pharmaceuticals, Inc.
  • Biodegradable lipids for the delivery of active agents
    Patent number: 11071784
    Abstract: The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.
    Type: Grant
    Filed: July 23, 2019
    Date of Patent: July 27, 2021
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Martin Maier, Muthusamy Jayaraman, Akin Akinc, Shigeo Matsuda, Pachamuthu Kandasamy, Kallanthottathil G. Rajeev, Muthiah Manoharan
  • Insulin-like growth factor binding protein, acid labile subunit (IGFALS) and insulin-like growth factor 1 (IGF-1) iRNA compositions and methods of use thereof
    Patent number: 11066670
    Abstract: The present invention relates to RNAi agents, e.g., double stranded RNAi agents, targeting the insulin-like growth factor binding protein, acid labile subunit (IGFALS) gene or the insulin-like growth factor 1 (IGF-1) gene, methods of using such double stranded RNAi agents to inhibit expression of an IGFALS gene or an IGF-1 gene, and methods of treating subjects having an IGF system-associated disorder.
    Type: Grant
    Filed: October 15, 2019
    Date of Patent: July 20, 2021
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: James Butler, Kevin Fitzgerald, Gregory Hinkle, Brian Bettencourt, Huilei Xu
  • Hepatitis B virus (HBV) iRNA compositions and methods of use thereof
    Patent number: 11060091
    Abstract: The present invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the hepatitis B virus (HBV) genome, and methods of using such RNAi agents to inhibit expression of one or more HBV genes and methods of treating subjects having an HBV infection and/or HBV-associated disorder, e.g., chronic hepatitis B infection.
    Type: Grant
    Filed: November 4, 2019
    Date of Patent: July 13, 2021
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Gregory Hinkle, Laura Sepp-Lorenzino, Vasant Jadhav, Martin Maier, Stuart Milstein, Muthiah Manoharan, Kallanthottathil G. Rajeev
  • Multi-targeted single entity conjugates
    Patent number: 11053495
    Abstract: The present invention relates, in general to, compounds, compositions and methods useful for modulating gene expression of multiple target nucleic acids by a single chemical entity.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: July 6, 2021
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Vasant Jadhav, Martin Maier, Ivan Zlatev, Akin Akinc, Kallanthottathil G. Rajeev, Jayaprakash K. Nair, Pachamuthu Kandasamy, Muthiah Manoharan
  • Patatin-like phospholipase domain containing 3 (PNPLA3) iRNA compositions and methods of use thereof
    Patent number: 11052103
    Abstract: The present invention relates to RNAi agents, e.g., double stranded RNAi agents, targeting the Patatin-Like Phospholipase Domain Containing 3 (PNPLA3) gene, and methods of using such RNAi agents to inhibit expression of a PNPLA3 gene and methods of treating subjects having Nonalcoholic Fatty Liver Disease (NAFLD) and/or a PNPLA3-associated disorder.
    Type: Grant
    Filed: February 5, 2019
    Date of Patent: July 6, 2021
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Kevin Fitzgerald, Gregory Hinkle
  • Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof
    Patent number: 11034958
    Abstract: The present invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the apolipoprotein C3 (APOC3) gene, and methods of using such RNAi agents to inhibit expression of APOC3 and methods of treating subjects having an APOC3 associated disorder, e.g., hypertriglyceridemia.
    Type: Grant
    Filed: December 21, 2020
    Date of Patent: June 15, 2021
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Kevin Fitzgerald, William Querbes, James Butler, Stephanie Williams, Abigail Liebow, Gregory Hinkle, Martin A. Maier, Stuart Milstein, Satyanarayana Kuchimanchi, Muthiah Manoharan
  • Amyloid precursor protein (APP) RNAi agent compositions and methods of use thereof
    Patent number: 11034957
    Abstract: The disclosure relates to double stranded ribonucleic acid (dsRNAi) agents and compositions targeting the APP gene, as well as methods of inhibiting expression of an APP gene and methods of treating subjects having an APP-associated disease or disorder, such as cerebral amyloid angiopathy (CAA) and early onset familial Alzheimer disease (EOFAD or eFAD), using such dsRNAi agents and compositions.
    Type: Grant
    Filed: July 9, 2020
    Date of Patent: June 15, 2021
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Stuart Milstein, Kirk Brown, Jayaprakash Nair, Martin Maier, Vasant Jadhav, Mark Keating, Adam Castoreno, Patrick Haslett, Mangala Meenakshi Soundarapandian, Kevin Fitzgerald
  • Compositions and methods for inhibiting expression of the ALAS1 gene
    Patent number: 11028392
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ALAS1 gene, and methods of using such dsRNA compositions to alter (e.g., inhibit) expression of ALAS1.
    Type: Grant
    Filed: September 20, 2018
    Date of Patent: June 8, 2021
    Assignees: Alnylam Pharmaceuticals, Inc., ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
    Inventors: Brian Bettencourt, Kevin Fitzgerald, William Querbes, Robert J. Desnick, Makiko Yasuda
  • Angiotensinogen (AGT) iRNA compositions and methods of use thereof
    Patent number: 11015201
    Abstract: The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the AGT gene. The invention also relates to methods of using such RNAi agents to inhibit expression of an AGT gene and to methods of preventing and treating an AGT-associated disorder, e.g., high blood pressure.
    Type: Grant
    Filed: November 10, 2020
    Date of Patent: May 25, 2021
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Donald Foster, Gregory Hinkle, Mark K. Schlegel
  • iRNA agents with biocleavable tethers
    Patent number: 11015194
    Abstract: The invention relates to iRNA agents, which preferably include a monomer in which the ribose moiety has been replaced by a moiety other than ribose that further includes a tether having one or more linking groups, in which at least one of the linking groups is a cleavable linking group. The tether in turn can be connected to a selected moiety, e.g., a ligand, e.g., a targeting or delivery moiety, or a moiety which alters a physical property. The cleavable linking group is one which is sufficiently stable outside the cell such that it allows targeting of a therapeutically beneficial amount of an iRNA agent (e.g., a single stranded or double stranded iRNA agent), coupled by way of the cleavable linking group to a targeting agent—to targets cells, but which upon entry into a target cell is cleaved to release the iRNA agent from the targeting agent.
    Type: Grant
    Filed: July 23, 2018
    Date of Patent: May 25, 2021
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev
  • Serpina1 iRNA compositions and methods of use thereof
    Patent number: 10995336
    Abstract: The invention relates to RNAi agents, e.g., double stranded RNAi agents, targeting the Serpina1 gene, and methods of using such RNAi agents to inhibit expression of Serpina1 and methods of treating subjects having a Serpina1 associated disease, such as a liver disorder.
    Type: Grant
    Filed: May 23, 2019
    Date of Patent: May 4, 2021
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Mark K. Schlegel, Maja Janas, Vasant R. Jadhav, Donald Foster, Muthiah Manoharan, Kallanthottathil G. Rajeev, Alexander V. Kel'in, Klaus Charisse, Jayaprakash K. Nair, Martin A. Maier, Shigeo Matsuda, Muthusamy Jayaraman, Alfica Sehgal, Christopher Brown, Kevin Fitzgerald, Stuart Milstein
  • TMPRSS6 iRNA compositions and methods of use thereof
    Patent number: 10988768
    Abstract: The invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the TMPRSS6 gene, and methods of using such RNAi agents to inhibit expression of TMPRSS6 and methods of treating subjects having a TMPRSS6 associated disorder, e.g., an iron overload associated disorder, such as ?-thalassemia or hemochromatosis.
    Type: Grant
    Filed: August 18, 2020
    Date of Patent: April 27, 2021
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: James Butler, Brian Bettencourt, Kallanthottathil G. Rajeev, Martin A. Maier, Klaus Charisse
  • Polynucleotide agents targeting programmed cell death 1 ligand 1 (PD-L1) and methods of use thereof
    Patent number: 10982215
    Abstract: The invention relates to polynucleotide agents targeting programmed cell death 1 ligand 1 (PD-L1) gene, and methods of using such polynucleotide agents to inhibit expression of PD-L1 and to treat subjects having a PD-L1-associated disorder.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: April 20, 2021
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventor: Gregory Hinkle
  • Conserved HBV and HCV sequences useful for gene silencing
    Patent number: 10982212
    Abstract: Conserved consensus sequences from known hepatitis B virus strains and known hepatitis C virus strains, which are useful in inhibiting the expression of the viruses in mammalian cells, are provided. These sequences are useful to silence the genes of HBV and HCV, thereby providing therapeutic utility against HBV and HCV viral infection in humans.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: April 20, 2021
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Catherine J Pachuk, Chandrasekhar Satishchandran, Vincent R. Zurawski, Liat Mintz
  • Polynucleotide agents targeting aminolevulinic acid synthase-1 (ALAS1) and uses thereof
    Patent number: 10968452
    Abstract: The invention relates to polynucleotide agents, e.g., antisense polunucleotide agents, targeting the ALAS1 gene, and methods of using such agents to alter (e.g., inhibit) expression of ALAS1 and to treat ALAS1 associated diseases, e.g., porphyria.
    Type: Grant
    Filed: March 30, 2017
    Date of Patent: April 6, 2021
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventor: Gregory Hinkle
  • COMPOSITIONS AND METHODS DIRECTED TO TREATING LIVER FIBROSIS
    Publication number: 20210087218
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the COL1A1, TGF-?, and SMAD2/3 genes, and methods of using such dsRNA compositions to inhibit expression of COL1A1, TGF-?, and SMAD2/3.
    Type: Application
    Filed: May 6, 2020
    Publication date: March 25, 2021
    Applicant: Alnylam Pharmaceuticals, Inc.
    Inventors: Gregory Hinkle, Victor Kotelianski, Brian Bettencourt, Alfica Sehgal, Tatiana Novobrantseva
  • GNAQ targeted dsRNA compositions and methods for inhibiting expression
    Patent number: 10954516
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a G-alpha q subunit (GNAQ) of a heterotrimeric G gene, and methods of using the dsRNA to inhibit expression of GNAQ.
    Type: Grant
    Filed: April 3, 2018
    Date of Patent: March 23, 2021
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Jared Gollob, Gregory Hinkle, Ivanka Toudjarska, David Bumcrot
  • Polynucleotide agents targeting hydroxyacid oxidase (glycolate oxidase, HAO1) and methods of use thereof
    Patent number: 10946107
    Abstract: The invention relates to polynucleotide agents targeting an hydroxyacid oxidase (HAO1) gene, and methods of using such polynucleotide agents to inhibit expression of HAO1 and to treat subjects having an HAO1-associated disease, e.g., hyperoxaluria.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: March 16, 2021
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventor: Gregory Hinkle
  • Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
    Patent number: 10934545
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ANGPTL3 gene, as well as methods of inhibiting expression of ANGPTL3 and methods of treating subjects having a disorder of lipid metabolism, such as hyperlipidemia or hypertriglyceridemia, using such dsRNA compositions.
    Type: Grant
    Filed: May 14, 2019
    Date of Patent: March 2, 2021
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Brian Bettencourt, William Querbes, Kevin Fitzgerald, Maria Frank-Kamenetsky, Stuart Milstein, Svetlana Shulga Morskaya
  • Serpina1 siRNAs: compositions of matter and methods of treatment
    Patent number: 10935917
    Abstract: The technology described herein relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the Serpina 1 gene, and methods of using such dsRNA compositions to inhibit expression of Serpina 1.
    Type: Grant
    Filed: July 17, 2019
    Date of Patent: March 2, 2021
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Alfica Sehgal, David Bumcrot, Brian Bettencourt